Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Sacha I Rothschild

14PUBLICATIONS
62CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersNeurology and neuromuscular diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

Sort by Publication Date:
|May 29, 2026
Addition of Intravesical Recombinant Bacillus Calmette-Guérin to Perioperative Chemoimmunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/19.

|Oct 21, 2025
Treatment patterns and clinical outcomes in stage III non-small-cell lung cancer: a long-term institutional experience in Switzerland.

Altay Turunç, David König, Judith Hafer

|Sep 30, 2025
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy.

Dominic Schmid, Bettina Sobottka, Massimiliano Manzo

|Jul 21, 2025
<i>ROS1</i> fusion-positive non-small cell lung cancer-repotrectinib as a new treatment option.

Sacha I Rothschild, Laetitia A Mauti

|Apr 13, 2024
Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis.

Oliver Illini, Felix Carl Saalfeld, Petros Christopoulos

|Mar 08, 2024
Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine.

Luca Afferi, Martin Spahn, Stefanie Hayoz

Pageof 3

Frequent Collaborators

3 joint publications

Ilaria Alborelli

3 joint publications

Stefanie Hayoz

3 joint publications

Richard Cathomas

3 joint publications

Nicolas Mach

2 joint publications

Stefanie Aeppli

2 joint publications

Laetitia A Mauti

2 joint publications

Lukas Bubendorf

2 joint publications

Jana Musilova

2 joint publications

Solange Peters

2 joint publications

Michel Gonzalez

Frequent Collaborators

3 joint publications

Ilaria Alborelli

3 joint publications

Stefanie Hayoz

3 joint publications

Richard Cathomas

3 joint publications

Nicolas Mach